Gene · 7296
NIH grants2,024
NIH grants whose papers are about the gene, through NIH's grant-paper links.
181 to 200 of 2,024
Download this page as JSON| Grant | Title | TXNRD1 papers | Newest fiscal year |
|---|---|---|---|
| R01AR073004 | Mechanism of action and function of novel secosteroid 20(OH)D3 in the skin | 1 | 2025 |
| R01CA053840 | Protein Tyrosine Dephosphorylation & Signal Transduction | 1 | 2025 |
| R01CA129933 | Modeling Metastasis and Acquired Drug Resistance Using Circulating Tumor Cells | 1 | 2025 |
| R01CA157823 | Genetic Susceptibility and Biomarkers of Platinum-related Toxicities | 1 | 2025 |
| R01CA163591 | Tumor cell metabolism in action | 1 | 2025 |
| R01CA172310 | Novel Targeted Anticancer Agents from Marine Cyanobacteria | 1 | 2025 |
| R01CA181745 | Optimizing radiation therapy through the manipulation of glutamine metabolism | 1 | 2025 |
| R01CA228137 | Roles of tGLI1 and microRNA Network in Breast Cancer Brain Metastasis | 1 | 2025 |
| R01CA256945 | Mechanisms of cell death in cutaneous melanoma | 1 | 2025 |
| R01CA257505 | Targeting Systems Vulnerabilities in the Gαq/GNAQ Oncogenic Signaling Circuitry: New Precision Therapies for Uveal Melanoma | 1 | 2025 |
| R01CA258421 | Gold-derived therapeutic compounds for disease application | 1 | 2025 |
| R01CA259845 | Fatty acid metabolism regulates ferroptosis in mutant KRAS lung cancer | 1 | 2025 |
| R01CA260857 | Multiplexed time domain fluorescence tomography of tumor biomarkers during immunotherapy | 1 | 2025 |
| R01CA260872 | A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients | 1 | 2025 |
| R01CA263506 | MiR-152/PKM2/SLC7A5 axis in breast cancer development, chemo- and radiation-treatment response | 1 | 2025 |
| R01CA266478 | Prolidase Inhibitors as Therapeutic Agents for Acute Myeloid Leukemia | 1 | 2025 |
| R01CA273238 | Glutaredoxin, Glutathione Metabolism and Lung Cancer | 1 | 2025 |
| R01DA058700 | Domain- and protein-selective BET mechanisms in cocaine-seeking behaviors | 1 | 2025 |
| R01DK032083 | Multiple Autoantigens, Multiple Epitopes of Type 1 Diabetes | 1 | 2025 |
| R01DK045776 | B12 Trafficking and Inherited Defects | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7296/grants?page=10